- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02881658
The Effect of 3-Week Consumption of Soya Beverage Enriched With Plant Sterols on Serum LDL-C
The Effect of Soya Beverage Fortified With Plant Sterol on Major Serum Lipids in Normocholesterolemic, Healthy Southern Chinese Individuals
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Hong Kong, Hong Kong
- Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Southern Chinese male or female ≥ 18 years;
- In good general health as evidenced by medical history;
- Have the ability to understand the requirements of the study, provide written informed consent, including consent for the use and disclose of research-related health information, and comply with the study data collection procedures. Provide signed and dated informed consent form
Exclusion Criteria:
- Subject with familial hypercholesterolemia;
On regular medication(s) which affect gastrointestinal functions and blood lipids level for the past 3 months, such as, but not limited to:
- Antibiotics of >1 week duration
- GI related medications such as antacids
- Having blood lipid lowering medications such as statins, selective cholesterol absorption inhibitors (e.g. ezetimibe), fibrates, niacin, resins, omega- 3
- Heavy-smokers (more than 1 pack per day)
- Subject with heavy alcohol intake (>40 g/day for men ; >30 g/day for women) (32), or having history of alcohol abuse within 12 months prior to the study
- Subjects with taste aversion to placebo/intervention soya beverages
Subject refusing to stop the consumption of plant sterols-enriched products if any during the study (other than the studied product) or having regular consumption of sterols/stanols cholesterol-lowering supplements/functional foods or other related products such as:
- Sterol/ Stanol - containing margarines, milk, yoghurt drink and soya beverages
- Sterol / Stanol supplements
- Fish oils & omega-3 supplements
- Subject receiving systemic treatment or topical treatment likely to interfere with evaluation of the study parameters
- Subject currently involved in a clinical trial or in an exclusion period following participation in another clinical trial
- Pregnancy or lactation
- Having soy allergy
- Being a vegan
- Being an athlete
- Concurrently participating in weight management or dietary program
- On diet pills, such as, but not limited to chitosan and dulcolax
- With history of sitosterolemia
- Having history of hypercholesterolemia, diabetes, thyroid disease, severe kidney diseases, cardiovascular diseases, chronic gastrointestinal disorders, cancers and AIDs ( acquired immune deficiency syndrome)
- Having history of malabsorption syndrome arising from diseases such as, but not limited to celiac disease, short bowel syndrome, cystic fibrosis, pancreatitis, diseases of gall-bladder, liver or pancreas, intestinal infection, injury, surgery and radiotherapy
- Taking over-the-counter Chinese medications or supplements with cholesterol/lipid lowering and related claims
- High blood cholesterol at screening [Total cholesterol level ≥6.22mmol/L]
- High LDL cholesterol [LDL cholesterol level ≥4.15mmol/L]
- High blood triglyceride at screening [Triglyceride ≥3.39mmol/L]
- Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Plant sterols-enriched soya beverage provided by Vitasoy
Daily consumption of 2g of plant sterols as provided by one pack of 250 ml of plant sterols-enriched soya beverage for consecutive 3 weeks, each pack consumed once with main meal (i.e breakfast, lunch or dinner).
|
the study product is a 2g plant sterols-enriched in 250ml soya beverage
|
PLACEBO_COMPARATOR: Soya beverage provided by Vitasoy
Daily consumption of one pack of 250 ml of soya beverage (without plant sterols) for consecutive 3 weeks, each pack consumed once with main meal (i.e breakfast, lunch or dinner).
|
the placebo product is a 250 ml soya beverage
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean of Serum Low-density Lipoprotein Cholesterol (LDL-C) Via Blood Test at Baseline and Week 3
Time Frame: From baseline to week 3
|
From baseline to week 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of Low Density Lipoprotein Cholesterol (LDL-C) Via Blood Test at Baseline and Week 3
Time Frame: From baseline to week 3
|
From baseline to week 3
|
|
Change of High-density Lipoprotein Cholesterol (HDL-C) Via Blood Test at Baseline and Week 3
Time Frame: From baseline to week 3
|
From baseline to week 3
|
|
Change of Total Cholesterol Via Blood Test at Baseline and Week 3
Time Frame: From baseline to week 3
|
From baseline to week 3
|
|
Change of Triglycerides (TAG) Via Blood Test at Baseline and Week 3
Time Frame: From baseline to week 3
|
From baseline to week 3
|
|
Change of Serum Creatinine Via Blood Test at Baseline and Week 3
Time Frame: From baseline to week 3
|
From baseline to week 3
|
|
Changes of Fasting Blood Glucose Via Blood Test at Baseline and Week 3
Time Frame: From baseline to week 3
|
From baseline to week 3
|
|
Changes of Cardiometabolic Risk Factors Via Measuring Anthropometry at Baseline and Week 3
Time Frame: From baseline to week 3
|
From baseline to week 3
|
|
Changes of Cardiometabolic Risk Factors Via Measuring Blood Pressure at Baseline and Week 3
Time Frame: From baseline to week 3
|
From baseline to week 3
|
|
Changes of Cardiometabolic Risk Factors Via Measuring Body Temperature at Baseline and Week 3
Time Frame: From baseline to week 3
|
From baseline to week 3
|
|
Changes of Musculoskeletal-related Traits Via Measuring Hand Grip Strength at Baseline and Week 3
Time Frame: From baseline to week 3
|
From baseline to week 3
|
|
Changes of Musculoskeletal-related Traits Via Measuring Bio-Impedance at Baseline and Week 3
Time Frame: From baseline to week 3
|
From baseline to week 3
|
|
Changes of Musculoskeletal-related Traits Via Measuring Peak Expiratory Flow Rate at Baseline and Week 3
Time Frame: From baseline to week 3
|
From baseline to week 3
|
|
Changes of Musculoskeletal-related Traits Via Measuring 6 Metres Gait Speed at Baseline and Week 3
Time Frame: From baseline to week 3
|
From baseline to week 3
|
|
Changes of Musculoskeletal-related Traits Via Measuring Centre of Pressure Excursion Index for Left and Right Foot at Baseline and Week 3
Time Frame: From baseline to week 3
|
centre of pressure excursion index = CPEI
|
From baseline to week 3
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Bernard Man Yung Cheung, Li Ka Shing Faculty of Medicine, The University of Hong Kong
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CTC1521
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyslipidemia
-
Chong Kun Dang PharmaceuticalCompletedDyslipidemia (Fredrickson Type Ⅱa) | Dyslipidemia (Fredrickson Type Ⅱb)Korea, Republic of
-
Kowa Research Institute, Inc.CompletedMixed Dyslipidemia | Primary DyslipidemiaUnited States
-
Hanlim Pharm. Co., Ltd.RecruitingMixed DyslipidemiaKorea, Republic of
-
IlDong Pharmaceutical Co LtdNot yet recruiting
-
Arrowhead PharmaceuticalsCompletedMixed DyslipidemiaUnited States, Australia, Poland, New Zealand, Canada, Hungary
-
Provident Clinical ResearchReliant PharmaceuticalsCompleted
-
Addpharma Inc.Recruiting
-
University of GuadalajaraCompleted
-
Esperion Therapeutics, Inc.CompletedMild DyslipidemiaUnited States
-
Hanlim Pharm. Co., Ltd.Completed